[HTML][HTML] Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
J Haanen, MS Ernstoff, Y Wang, AM Menzies… - Annals of oncology, 2020 - Elsevier
Highlights•Solid organ transplantation (SOT) patients or patients with active ADs have been
largely excluded from ICIs clinical trials because of the risk of allograft rejection or severe …
largely excluded from ICIs clinical trials because of the risk of allograft rejection or severe …
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
J Haanen, MS Ernstoff, Y Wang… - Annals of …, 2020 - mdanderson.elsevierpure.com
Patients with cancer and with preexisting active autoimmune diseases (ADs) have been
excluded from immunotherapy clinical trials because of concerns for high susceptibility to …
excluded from immunotherapy clinical trials because of concerns for high susceptibility to …
[HTML][HTML] Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
J Haanen, MS Ernstoff, Y Wang… - Annals of …, 2020 - annalsofoncology.org
Patients with cancer and with preexisting active autoimmune diseases (ADs) have been
excluded from immunotherapy clinical trials because of concerns for high susceptibility to …
excluded from immunotherapy clinical trials because of concerns for high susceptibility to …
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy.
J Haanen, MS Ernstoff, Y Wang… - Annals of Oncology …, 2020 - europepmc.org
Patients with cancer and with preexisting active autoimmune diseases (ADs) have been
excluded from immunotherapy clinical trials because of concerns for high susceptibility to …
excluded from immunotherapy clinical trials because of concerns for high susceptibility to …
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy.
J Haanen, MS Ernstoff, Y Wang, AM Menzies… - Annals of oncology …, 2020 - folia.unifr.ch
English Patients with cancer and with preexisting active autoimmune diseases (ADs) have
been excluded from immunotherapy clinical trials because of concerns for high susceptibility …
been excluded from immunotherapy clinical trials because of concerns for high susceptibility …
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
J Haanen, MS Ernstoff, I Puzanov, Y Wang… - Annals of …, 2020 - elibrary.ru
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the
literature and personalized risk-based prevention strategy КОРЗИНА ПОИСК НАВИГАТОР …
literature and personalized risk-based prevention strategy КОРЗИНА ПОИСК НАВИГАТОР …
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
J Haanen, MS Ernstoff, Y Wang… - Annals of oncology …, 2020 - pubmed.ncbi.nlm.nih.gov
Patients with cancer and with preexisting active autoimmune diseases (ADs) have been
excluded from immunotherapy clinical trials because of concerns for high susceptibility to …
excluded from immunotherapy clinical trials because of concerns for high susceptibility to …
[引用][C] Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
J Haanen, MS Ernstoff, Y Wang, AM Menzies… - Annals of …, 2020 - cir.nii.ac.jp
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the
literature and personalized risk-based prevention strategy | CiNii Research CiNii 国立情報学 …
literature and personalized risk-based prevention strategy | CiNii Research CiNii 国立情報学 …
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy.
J Haanen, MS Ernstoff, Y Wang, AM Menzies… - Annals of oncology …, 2020 - sonar.ch
English Patients with cancer and with preexisting active autoimmune diseases (ADs) have
been excluded from immunotherapy clinical trials because of concerns for high susceptibility …
been excluded from immunotherapy clinical trials because of concerns for high susceptibility …
[PDF][PDF] Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
J Haanen, MS Ernstoff, Y Wang, AM Menzies… - researchgate.net
Patients with cancer and with preexisting active autoimmune diseases (ADs) have been
excluded from immunotherapy clinical trials because of concerns for high susceptibility to …
excluded from immunotherapy clinical trials because of concerns for high susceptibility to …